Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by 90guppyon May 29, 2020 1:05pm
82 Views
Post# 31088538

RE:RE:RE:RE:st peter, you sent me a pm

RE:RE:RE:RE:st peter, you sent me a pmwith all due respect st.peter, I dont think the email below is legit.  Given your real name is Keith, but the suspect part is your email is info@vaxil.com. That is very odd.


saintpeter wrote: this is for only so many eyes for a calmer board if you get my drift
-----Original Message-----
From: Keith  <info@vaxil-bio.com>
Sent: Thursday, May 28, 2020 6:10 PM
To: David Goren <david.goren@epionehp.com>
Subject: PP

From: Keith
Subject: PP

Message Body:
Hello David
 I'm sure that you are aware of the outcome of this has done to the market share price. I would like to know why this wasn't put out in a new release ahead of time there are a lot of loyal investors loosing their shirts because of this blind side especially when a couple of week ago you said no funds needed and I know these things take time to arrange so please give me the courtesy of a reply to this email

thankyou for your time on this matter

Keith





this is his reply
Hi Keith.

I hope you are well.

We issue press releases to inform shareholders and others when we have meaningful results to report - including scientific and financial. We cannot issue press releases that are speculative.  In any company, there will always be a variety of discussions and negotiations going on, some of which will conclude in a deal and others won't. The release is issued only if and once the deal is done.  These are the rules we and all companies are required to follow.

The press release for the fund raise was issued in keeping with regulatory requirements and guidelines.

In addition, we have always said that we need to raise money to progress our program, including in each and every financial statement release (quarterly and annual).  We are obligated to explore all options so that we ensure the best possible outcome for investors both in the short- and long-term. This funding is necessary in that context.

Thanks for taking the time to write and I wish you good health, Keith.

David



<< Previous
Bullboard Posts
Next >>